With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...

Women who developed a cardiovascular disease or type 2 diabetes were at a higher risk of developing breast cancer post ...

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with ...

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Many FDA accelerated approvals continue to rely heavily on surrogate endpoints, raising ongoing uncertainty about the true clinical benefits of these therapies.

A panelist discusses how oral combination therapy with decitabine-cedazuridine plus venetoclax shows activity in the relapsed/refractory acute myeloid leukemia setting, achieving responses even in ...

A panelist discusses how the shift from intravenous to oral AML therapies addresses significant quality-of-life concerns by eliminating the burden of spending 7 days per month in clinics for infusions ...

Panelists discuss how payers seek good return on investment when evaluating expensive gene therapies, creating potential friction when innovative treatments come at significant costs, requiring ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.